论文部分内容阅读
目的:研讨脑梗塞患者合用血塞通与依达拉奉治疗的临床适用性与安全性。方法:从我院2012年3月至2015年12月选取62例脑梗塞患者进行试验,Ⅰ、Ⅱ组各31例,各采取单纯依达拉奉方案、依达拉奉合用血塞通方案治疗,评估该两种方案的给药情况。结果:与Ⅰ组(74.2%)相比,Ⅱ组总治疗有效率(93.5%)显著提高,有统计学意义(P<0.05)。经神经功能缺损评测,显示两组治疗前的评测结果基本无差异,无统计学意义(P>0.05),但治疗后,Ⅱ组的评测结果(83.82±10.25)分,相比Ⅰ组的(68.54±7.51)分有显著提高,有统计学意义(P<0.05)。两组在治疗期间均未产生严重副作用。结论:合用血塞通与依达拉奉方案在脑梗塞的治疗中具有适用性,且安全可靠,有推广意义。
Objective: To investigate the clinical applicability and safety of Xuesaitong and edaravone in patients with cerebral infarction. Methods: Sixty-two patients with cerebral infarction were selected from March 2012 to December 2015 in our hospital. Thirty-one patients in group Ⅰ and Ⅱ were treated with Edaravone and Edaravone combined with Xuesaitong , To assess the administration of the two programs. Results: Compared with group Ⅰ (74.2%), the total effective rate (93.5%) in group Ⅱ was significantly increased (P <0.05). The results of neurological deficit evaluation showed that there was no significant difference between the two groups before treatment (P> 0.05), but after the treatment, the results of group Ⅱ (83.82 ± 10.25) 68.54 ± 7.51) was significantly increased, with statistical significance (P <0.05). Both groups had no serious side effects during treatment. Conclusion: The combination of Xuesaitong and Edaravone has applicability in the treatment of cerebral infarction, and is safe and reliable, which has the promotion significance.